COVID-19 Guidelines Use of Directly Acting Antivirals in Adults Drug-Drug Interactions Drug-Drug Interactions Drug-Drug Interactions Drug-Drug Interactions Drug-Drug Interactions Drug-Drug Interactions DDI Resources for COVID-19 Antivirals The Liverpool DDI Tool www.covid19-druginteractions.org DDI Searches Returned Liverpool Tool Mixpanel Stats Prevalence of DDIs With COVID-19 Antivirals Prevalence of DDIs by Type Prevalence of DDIs by Type Ritonavir Is a Mixed Inducer and Inhibitor Ritonavir Is a Mixed Inducer and Inhibitor Ritonavir Is a Mixed Inducer and Inhibitor Beyond the COVID-19 DDI Tool Not Problematic/Mostly Manageable DDIs Not Problematic/Mostly Manageable DDIs Not Problematic/Mostly Manageable DDIs Not Problematic/Mostly Manageable DDIs Problematic/Challenging DDIs Problematic/Challenging DDIs Additional DDI Considerations Prolonged and Repeated Courses of NMVr Prolonged and Repeated Courses of NMVr Prolonged and Repeated Courses of NMVr Prolonged and Repeated Courses of NMVr Ensitrelvir SCORPIO Trial Primary Endpoint Time to Resolution of 5 COVID-19 Symptoms Ensitrelvir SCORPIO Trial Long COVID Symptoms ENS Metabolism and Effect on Drug- Metabolizing Enzymes Fraction of CYP3A4 Metabolism and Magnitude/Duration of DDI With ENS Fraction of CYP3A4 Metabolism and Magnitude/Duration of DDI With ENS Beyond the COVID-19 DDI Tool Patient Case 1 Patient Case 1 March 2023 Patient Case 1 April 2023 Patient Case 1 April 2023 Patient Case 1 April 2023 Administration in Cases of Swallowing Difficulties COVID-19 Drug Interactions Patient Case 2 Patient Case 2 COVID-19 Drug Interactions (cont) COVID-19 Drug Interactions (cont) COVID-19 Drug Interactions (cont) COVID-19 Drug Interactions (cont) COVID-19 Drug Interactions (cont) COVID-19 Drug Interactions (cont) Antiviral Dose Recommendations for Patients With Kidney Impairment Tacrolimus Tacrolimus Tacrolimus-Related Case Reports Tacrolimus Tacrolimus Demystifying COVID-19 Drug Interactions Demystifying COVID-19 Drug Interactions Thank You